# Clinical OS v5.1 — Hyponatremia Editor Trial | Audit and Evaluation
Date: 2026-10-21
Status: **HOLD (editorial trial, not published; no external physician review)**

## A. Experimental identity
- Input topic selected autonomously from user's Pocket Medicine ninth edition: **Hyponatremia**.
- Run with actual Clinical_system rules from \`docs/master-prompt-v5.1-architecture.md\`, \`docs/editorial-prose-quality-contract.md\`, \`docs/xiaoma-depth-standard.md\`, \`docs/learning-experience-contract.md\`, and \`docs/xiaoma-evidence-expansion.md\`.
- Prior original Xiaoma HCM full text **not fetched/read during this run**. However, EPQC rules explicitly describe HCM's cognitive distinctions and previous user conversation contains historical quality guidance. This is **a fresh-topic, rubric-informed study, not a true content-and-model-blind randomized comparison**.
- The assistant previously authored a PE draft in the same conversation. **PE vs. Hyponatremia is not a controlled A/B test**, so no quantitative claim of performance uplift from adding Clinical OS can be made.
- Content deliberately isolated on branch \`experiment-hyponatremia-clinical-os-20261021\`, no change to main and no production publishing entry in site/pages.json.

## B. Evidence and Figure/Table verification ledger
| ID | Assertion / curricular implication | Source and actual inspection | Boundaries / improvement |
| --- | --- | --- | --- |
| HYPO-E01 | Serum Na concentration is a function of exchangeable Na+K relative to TBW; true hypotonicity must be distinguished from hyperglycemia and pseudohyponatremia. | Pocket 9e PDF pp.166–167; JCEM 2022 review (full readable web text) | Distinguish measured osmolality from *effective* tonicity; urea adds osmolality without acting as typical effective osmole. |
| HYPO-E02 | Concentrated urine doesn't prove SIAD; distinguish baroreceptor-driven antidiuresis and other etiologies. | Pocket 9e p.167 Fig. 4-4 visually inspected, captions/branches checked; JCEM 2022 Table 4/5 | Figure begins **after** hypotonicity confirmed; do not claim book omitted initial tonicity check. Clinical euvolemia classification has limited accuracy. |
| HYPO-E03 | SIAD + isotonic saline may worsen serum sodium (*desalination*), but UOsm alone doesn't provide a universal cutoff. | Pocket 9e p.168 diagram/table visually inspected and text extracted; JCEM 2022 review | Book's UOsm 616 mOsm example is *illustrative*, not a validated universal rule. Urea and urine Na+K vs water balance matter. |
| HYPO-E04 | Suppression of AVP after correcting hypovolemia can cause sudden water diuresis, with faster-than-predicted sodium rise. | Pocket 9e p.168 text; Sterns et al. CJASN 2024 full text | Need monitor UOP and serial serum sodium; not only infusion rate. |
| HYPO-E05 | Severe neurological manifestations warrant prompt partial hypertonic correction regardless of completing full diagnostic work-up. | European guideline 2014 §7.1 (100% text checked for major bolus advice); JCEM 2022 Table 6; NDT 2024 review | US 100 mL/10 min vs Europe 150 mL/20 min are **distinct protocols**, not combine doses blindly; corrective target 4–6 mmol/L, not full normalization. |
| HYPO-E06 | Chronic hyponatremia/high ODS-risk needs correction ceilings and may warrant DDAVP ± D5W rescue under expert monitoring. | Sterns et al. CJASN 2024, published full PMC content; EJE guideline 2014 | Different guideline populations/limits; 8 mmol/L/24h is an upper bound for high-risk, not a desired daily rise. |
| HYPO-E07 | SALSA rapid intermittent bolus was not statistically superior for overcorrection: 17.2% vs 24.2%, p=.26. | Baek et al. JAMA IM 2021 full text Table 2, primary endpoint; supplementary listings seen but appendices not fully inspected | Do not call non-significant difference equal safety or claim confirmed reduction in overcorrection. Restricted high-risk generalizability. |
| HYPO-E08 | Urine electrolyte-to-serum Na ratio may predict restriction failure only imperfectly. | JCEM 2022 review; 2025 prospective multicenter cohort retrieved in initial research | Not treated as a definitive threshold or inserted into core algorithm; sample selection and prospective validation needed. |

## C. EPQC seven-axis *self-assessment*, with textual anchors
The system uses 0–4 scales. This assessment is **same-agent preliminary**, not independent, and cannot prove noninferiority.
| Axis | Score | Reason/observable evidence |
| --- | --- | --- |
| A Main proposition and exclusion | 4 | Single governing question: why removing the initial water-retention driver makes sodium correction unpredictable. |
| B Concept disentangling | 4 | Separates Na concentration vs total Na; osmolality vs tonicity; antidiuresis vs SIAD; UOsm vs electrolyte-free water handling; correction goal vs ceiling. |
| C Necessary causal intermediates | 4 | AVP pressure signal → aquaporin water retention → correction of cause → water diuresis → rapid Na rise → chronic brain adaptation risk. |
| D Evidence changes decision | 3 | ESC/US initial bolus distinctions, SALSA null main comparison; follow-up protocol and complex etiologies remain practice-dependent. |
| E Narrative continuity | 3 | Recurring saline paradox supports full arc; multiple explanations could still be tightened for time-constrained reader. |
| F Counterfactual transfer | 4 | Four sequential contrasts: hypovolemia vs SIAD, emergence of seizure, sudden aquaresis. |
| G Language/cognitive burden | 3 | Dense prose with contextual definitions; 5-minute model and visuals still need independent reader test. |
**Raw self-rating: 25/28, mean 3.57**. Meets numerical authoring bar only if confirmed. Hard gates take precedence. Medical correctness/figure review remain unverified at external reviewer level; no publish recommendation.

## D. Adversarial audit and corrections baked into v1
1. **False inference avoided:** UOsm > 300 or UOsm > 308 does **not** by itself diagnose SIAD or prove saline will worsen hyponatremia.
2. **False sequence avoided:** The original Pocket figure already labels *hypotonic* hyponatremia, and surrounding text checks osmolality first. It is incorrect to call the original source entirely volume-first.
3. **Treat-before-classify edge:** seizures/severe cerebral symptoms cannot await completed etiologic categorization; risk of iatrogenic ODS must not be used as a reason to omit initial rescue.
4. **Trial nuance:** SALSA primary comparison was nonsignificant; did not establish lower overcorrection rates with bolus.
5. **Prediction limits:** no deterministic sodium prediction from input saline alone; ongoing loss, K replacement, solute repletion, and endocrine recovery dynamically change trajectory.
6. **Risk stratification:** ODS high-risk correction ceiling not conflated with desired correction and with acute cerebral edema rescue.
7. **Source integrity:** Figure 4-4 and Pocket fluid-table image were visually inspected, not copied to public source; publisher reproduction permission not established.

## E. What remains untested / acceptance blockers
- Medical independent reviewer required for management pathways, dosage, exclusions and severe neurological presentation.
- Figure 4-4 original visual cross-check done; cited guideline figure legend and all relevant supplementary clinical trial tables **not** exhaustively reviewed. Do not claim complete source audit.
- A genuine causal **Baseline vs Full Clinical OS** experiment requires two independent, non-communicating drafting contexts on the **same unseen topic**, identical sources and model configuration, then blinded graders and novel clinical cases. Same-context redrafting confounds comparison.
- Learning gain (time to correct mechanism, counterfactual accuracy, safety-error rate, cognitive burden) has not been measured on humans.
- No site publish/production deploy; no page registry modifications; no user historical originals altered.

## F. Decision
**Retain as promising system-assisted article draft; HOLD publication and any claim Clinical OS outperforms native AI.**

Next controlled trial: new topic selected by third-party or seeded before either arm, independent contexts, identical sources, randomized rubric visibility; two independent reviewers score accuracy/concept disentangling/time and clinical transfer. Must compare improvement vs setup/maintenance costs per v5.1 architecture principle.
